EUVIMEDEUVIMED entdecken
Crossref

Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175

Yongpeng Li, Lin Li, Haoyu Fu, Qing Yao, Lei Wang, Liguang Lou

American Journal of Cancer Research · 2026 · 16 (10) · 4674-4675

DOI: 10.62347/szdy9971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Yongpeng Li und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Li, Y., Li, L., Fu, H., Yao, Q., Wang, L., & Lou, L. (2026). Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175. American Journal of Cancer Research, 16(10), 4674-4675. https://doi.org/10.62347/szdy9971

Vancouver

Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175. American Journal of Cancer Research. 2026;16(10):4674-4675. doi:10.62347/szdy9971

BibTeX
@article{Li2026,
  author = {Li, Yongpeng and Li, Lin and Fu, Haoyu and Yao, Qing and Wang, Lei and Lou, Liguang},
  title = {Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175},
  journal = {American Journal of Cancer Research},
  year = {2026},
  volume = {16},
  number = {10},
  pages = {4674--4675},
  doi = {10.62347/szdy9971}
}
Kostenlos starten →